Chemed (CHE) Q1 2026 Earnings Call Transcript

Chemed delivered a strong quarter at VITAS, with admissions up 6.9%, revenue up 3.1% to $420 million, and adjusted EBITDA up 0.6% to $70.8 million, while raising full-year VITAS growth guidance and EPS guidance to $24.00-$24.75. Roto-Rooter was mixed: revenue fell modestly, adjusted EBITDA dropped 9.6% as marketing spend rose nearly $3 million and weather disrupted service, but management said the franchise acquisitions in San Francisco and Fort Worth are immediately accretive. Overall guidance improved mainly due to VITAS, though Roto-Rooter margins were trimmed because higher digital marketing costs are expected to persist.

Analysis

CHE’s core setup improved because the better segment is now subsidizing the weaker one. The VITAS beat is not just a quarter of cleaner execution; it materially de-risks the state-level reimbursement overhang and should compress the market’s fear discount around Florida cap leakage over the next 2-3 quarters. The more important second-order effect is hiring capacity: management is pulling FTEs back up, so the margin lift is likely not linear from here, but higher census plus normalized cap math should still support upward earnings revisions into mid-2026.

The Roto-Rooter story is more fragile than the headline guidance suggests. Search visibility is becoming a structural cost problem, not a one-off, and that means EBITDA is being re-rated by a mix shift toward paid traffic with a likely lag before any SEO improvements can offset it. Add weather volatility and franchise integration, and the business looks like a low-quality grower in the near term—good for top-line stability, but not for margin expansion.

The real contrarian point: the market may still be underestimating how powerful VITAS’ new Florida starts can be once they age into longer-stay cohorts. New markets are inherently short-stay at first, so current ADC is suppressing the future mix benefit; that creates a setup where 2H26 could surprise again even without heroic admissions growth. On the other hand, if Google keeps degrading organic lead flow, Roto-Rooter can remain a margin drag for longer than consensus expects, which caps multiple expansion even if consolidated EPS rises.

Catalyst timing matters: near-term, CHE likely trades on guidance credibility and any signs that VITAS hiring can keep pace without eroding margin. Over 3-6 months, the key debate is whether Roto-Rooter marketing is a permanent step-up or just a transition tax. If the latter, the stock has room to rerate; if not, this becomes a healthcare-led compounder with a shrinking-quality non-hospice franchise attached.

Key Decisions for Investors

• Long CHE common on 3-6 month horizon; the setup is favorable if the market starts capitalizing the VITAS guide raise and cap cushion improvement. Risk: multiple compression if Roto-Rooter marketing stays elevated and investors anchor on consolidated margin pressure.
• Pair trade: long CHE / short GOOGL for 1-2 quarters. Thesis: CHE is a direct victim of Google-driven lead inflation in one segment, while the article implies GOOGL’s search changes are extracting surplus from operators; risk is that Alphabet monetization remains resilient and CHE’s organic visibility recovers faster than expected.
• Sell downside protection on CHE via out-of-the-money puts 1-2 quarters out if implied vol remains elevated. The operating risk is real, but the VITAS upside/cap de-risking likely limits immediate downside unless Roto-Rooter worsens materially.
• Avoid chasing CHE after a gap-up; wait for a post-earnings consolidation or a pullback toward pre-call levels. Better entry is when the market re-weights the durable hospice reacceleration versus the temporary Roto-Rooter margin noise.
• For relative value, own hospice-exposed healthcare names versus home-services peers with heavier digital-acquisition dependency. CHE is showing that regulated demand with reimbursement tailwind is less fragile than lead-optimized service businesses facing algorithmic cost inflation.